君实生物双抗ADC获批临床；默沙东K药联合疗法获批新适应症 | 医药早参

每日经济新闻07:45

丨 2025年1月9日星期四丨　　NO.1 君实生物注射用JS212临床试验申请获受理　　1月8日，君实生物发布公告，称公司收到国家药品监督管理局核准签发的《受理通知书》，注射用JS212（项目代号“JS212”）的临床试验申请获得受理。公告显示，JS212是重组人源化抗表皮生长因子受体（简称“EGFR”）和人表皮生长因子受体3（简称“HER3”）双特异性抗体偶联药物（简称“ADC”），主要用于...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2502802620?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-01-09 07:45","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2502802620","market":"hk","top_or_hot":-1,"title":"君实生物双抗ADC获批临床；默沙东K药联合疗法获批新适应症 | 医药早参","media":"每日经济新闻","content":"<div>\n<p>丨 2025年1月9日星期四丨　　NO.1 君实生物注射用JS212临床试验申请获受理　　1月8日，君实生物发布公告，称公司收到国家药品监督管理局核准签发的《受理通知书》，注射用JS212（项目代号“JS212”）的临床试验申请获得受理。公告显示，JS212是重组人源化抗表皮生长因子受体（简称“EGFR”）和人表皮生长因子受体3（简称“HER3”）双特异性抗体偶联药物（简称“ADC”），主要用于...</p>\n\n<a href=\"http://finance.eastmoney.com/a/202501093291765269.html\">网页链接</a>\n\n</div>\n","source":"stock_eastmoney","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>君实生物双抗ADC获批临床；默沙东K药联合疗法获批新适应症 | 医药早参</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n君实生物双抗ADC获批临床；默沙东K药联合疗法获批新适应症 | 医药早参\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-01-09 07:45 北京时间&nbsp;&nbsp;&nbsp;<a href=http://finance.eastmoney.com/a/202501093291765269.html><strong>每日经济新闻</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>丨 2025年1月9日星期四丨　　NO.1 君实生物注射用JS212临床试验申请获受理　　1月8日，君实生物发布公告，称公司收到国家药品监督管理局核准签发的《受理通知书》，注射用JS212（项目代号“JS212”）的临床试验申请获得受理。公告显示，JS212是重组人源化抗表皮生长因子受体（简称“EGFR”）和人表皮生长因子受体3（简称“HER3”）双特异性抗体偶联药物（简称“ADC”），主要用于...</p>\n\n<a href=\"http://finance.eastmoney.com/a/202501093291765269.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1066051811.HKD","symbol_name":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (HKD) INC","start_time":0,"source_url":"http://finance.eastmoney.com/a/202501093291765269.html","article_id":"2502802620","we_media_id":null,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202501093291765269.html","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2502802620","pubTimestamp":1736379910,"columns":[],"sourceInfo":{"source_id":"stock_eastmoney","name":"东方财富"},"weMediaInfo":null,"summary":"丨2025年1月9日星期四丨NO.1君实生物注射用JS212临床试验申请获受理1月8日，君实生物发布公告，称公司收到国家药品监督管理局核准签发的《受理通知书》，注射用JS212（项目代号“JS212”）的临床试验申请获得受理。","collect":0,"end_time":0,"defaultTopTitle":"eastmoney.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU1066051811.HKD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (HKD) INC","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","LU2324357040.USD":"HSBC GIF GLOBAL EQUITY SUSTAINABLE HEALTHCARE \"AC\" (USD) ACC","LU2106854487.HKD":"ALLIANZ THEMATICA \"AMG\" (HKD) INC","LU2461242641.AUD":"WELLINGTON US QUALITY GROWTH \"A\" (AUDHDG) ACC","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","LU0208291251.USD":"FRANKLIN MUTUAL U.S. VALUE \"A\" (USD) INC","IE00BN8TJ469.HKD":"FTGF CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A\" (HKD) INC","LU0266013472.USD":"AXA WF - Framlington Longevity Economy A Cap USD","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","LU1989772923.USD":"CPR Invest - Climate Action A2 Acc USD-H","LU1116320901.HKD":"BGF SYSTEMATIC GLOBAL ENHANCED EQUITY YIELD \"A6\" (HKD) INC","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","LU2023250504.SGD":"Allianz Thematica Cl AMg DIS H2-SGD","LU2023250843.SGD":"Allianz Thematica Cl AT Acc H2-SGD","BK1161":"生物科技","LU0203345920.USD":"SCHRODER ISF QEP GLB ACT. VL \"A\" (USD) ACC","LU0234572021.USD":"高盛美国核心股票组合Acc","01877":"君实生物","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","LU1941712264.USD":"ALLIANZ PET AND ANIMAL WELLBEING \"A\" (USD) INC","LU2112291526.USD":"BGF WORLD HEALTHSCIENCE \"A4\" (USD) INC","LU2361044949.HKD":"WELLINGTON US QUALITY GROWTH \"A\" (HKD) ACC","ADC":"艾格里房产","MRK":"默沙东","LU0006306889.USD":"SCHRODER ISF US LARGE CAP \"A\" (USD) INC AV","SG9999014567.USD":"UOB UNITED INCOME FOCUS TRUST FUND (USD) ACC","LU2361045086.USD":"WELLINGTON US QUALITY GROWTH \"A\" (USD) ACC","IE00B1BXHZ80.USD":"Legg Mason ClearBridge - US Appreciation A Acc USD","LU0122379950.USD":"贝莱德世界健康科学A2","BK4516":"特朗普概念","LU1291159041.SGD":"CPR Invest - Global Silver Age A2 Acc SGD-H","LU0985320562.USD":"NORDEA 1 GLOBAL STARS EQUITY \"BP\" (USD) ACC","LU0203347892.USD":"SCHRODER ISF QEP GLOBAL ACTIVE VALLUE \"A\" (USD)  INC AV","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","LU1699723380.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"AP\" (USD) ACC","SG9999001440.SGD":"United Global Dividend Equity Fund A SGD Dist","BK4534":"瑞士信贷持仓","BK1574":"生物医药B类股","SG9999001176.USD":"United Global Healthcare Acc USD","BK4007":"制药","IE00BLSP4452.SGD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis SGD-H Plus","09939":"开拓药业-B","LU0265550359.USD":"BGF SYSTEMATIC GLOBAL ENHANCED EQUITY YIELD \"A2\" (USD) ACC","BK4080":"零售业房地产投资信托","SG9999001176.SGD":"UOB UNITED GLOBAL HEALTHCARE \"SGD\" (ACC)","SG9999014575.USD":"UOB UNITED INCOME FOCUS TRUST FUND (USDHDG) INC","LU0238689110.USD":"贝莱德环球动力股票基金","LU1989771016.USD":"东方汇理环球老龄化投资基金 A2 Acc","BK4559":"巴菲特持仓"},"translate_title":"Junshi Biotech's double antibody ADC was approved for clinical use; Merck's K-drug combination therapy approved for new indications, early medical participation","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09939":1,"ADC":1,"01877":1,"MRK":1},"content_text":"丨 2025年1月9日星期四丨　　NO.1 君实生物注射用JS212临床试验申请获受理　　1月8日，君实生物发布公告，称公司收到国家药品监督管理局核准签发的《受理通知书》，注射用JS212（项目代号“JS212”）的临床试验申请获得受理。公告显示，JS212是重组人源化抗表皮生长因子受体（简称“EGFR”）和人表皮生长因子受体3（简称“HER3”）双特异性抗体偶联药物（简称“ADC”），主要用于晚期恶性实体瘤的治疗。EGFR和HER3在多种肿瘤细胞表面存在高表达，如肺癌、乳腺癌、头颈部肿瘤等。　　点评：与单一靶点ADC药物相比，JS212能够通过与EGFR或HER3结合发挥肿瘤抑制作用，有望对更广泛的肿瘤有效，同时有望克服耐药性问题。临床前研究显示，JS212与EGFR和HER3的高亲和力、特异性结合作用，在多个动物模型中展示了显著的抑瘤作用。不过，本次临床试验申请能否获得批准存在不确定性，投资者需谨慎决策，注意防范投资风险。　　NO.2 默沙东联合疗法获批用于尿路上皮癌一线治疗　　1月8日，国家药品监督管理局（NMPA）官网显示，默沙东的帕博利珠单抗（K药）与安斯泰来注射用维恩妥尤单抗联合疗法获批上市，联合用于既往未经治疗的局部晚期或转移性尿路上皮癌（la/mUC）成年患者的一线治疗。帕博利珠单抗此前已在国内获批十多项适应症，涵盖黑色素瘤、非小细胞肺癌、食管鳞癌、头颈部鳞状细胞癌、结直肠癌等癌种。　　点评：默沙东的帕博利珠单抗（K药）联合安斯泰来注射用维恩妥尤单抗的疗法获批新适应症，不仅巩固了默沙东在肿瘤治疗领域的领先地位，也为尿路上皮癌患者提供了新的治疗选择，有望提升患者的生存率和生活质量。同时，K药的多适应症布局有助于分散单一适应症市场的风险，增强其在资本市场的吸引力。　　NO.3 康龙化成参与总额18.8亿元私募基金投资　　1月8日，康龙化成发布公告，称公司作为有限合伙人，出资2.6亿元人民币参与由关联方康君投资管理（北京）有限公司设立的宁波康君仲元股权投资合伙企业（有限合伙），该基金募集资金总额为18.8亿元。截至公告日，基金全体合伙人已完成实缴出资。各合伙人出资情况显示，康龙化成的认缴出资额占比为13.83%。此次投资事项将对公司的财务状况产生一定影响，具体情况将持续关注并及时披露。　　点评：此举表明公司正积极通过股权投资基金拓展业务版图，寻求新的增长点，同时也可能带来一定的财务风险和收益不确定性，投资者需持续关注其投资项目的进展和基金运作情况，以评估对公司财务状况的具体影响。　　NO.4 正海生物推出的第二款口腔修复膜产品获批　　1月8日，正海生物发布公告，称公司于近日取得国家药品监督管理局下发的医疗器械注册证，获批产品口腔修复膜适用于口腔颊部、腭部的软组织浅层缺损及牙龈黏膜组织的覆盖修复。针对口腔黏膜等口腔内软组织较大面积缺损，其以细胞支架的形式移植到缺损部位，为细胞提供生长的场所和空间，诱导和调节细胞的生长、分化和代谢，简化手术操作步骤，降低手术风险。　　点评：本次获批的口腔修复膜产品为正海生物推出的第二款口腔修复膜产品，是在已上市口腔修复膜（国械注准20153170386）产品的工艺基础上研发而成，有效提高了产品力学性能，更好地满足临床需求。该产品的取证获批进一步丰富了公司口腔领域产品，有助于巩固公司在口腔领域的领先地位，进一步扩大竞争优势，可能对公司股价产生积极影响。　　NO.5 人福药业奥卡西平口服混悬液在国内获批　　1月8日，人福药业发布公告，称控股子公司武汉人福药业有限责任公司近日收到国家药品监督管理局核准签发的奥卡西平口服混悬液的《药品注册证书》，该产品用于治疗原发性全面性强直-阵挛发作和部分性发作，伴有或不伴有继发性全面性发作，适用于成年人和2岁以上儿童。2023年度，奥卡西平口服混悬液全国销售额约为6000万元，主要厂商为Novartis Pharma Schweiz AG。　　点评：本次奥卡西平口服混悬液获批，标志着武汉人福具备了在国内市场生产销售该药品的资格，进一步丰富了公司的产品线，其上市销售将给公司带来积极影响。不过，该产品未来的具体销售情况可能受到行业政策、市场环境等因素影响，具有不确定性，需要广大投资者谨慎决策，注意防范投资风险。　　免责声明：本文内容与数据仅供参考，不构成投资建议，使用前请核实。据此操作，风险自担。（文章来源：每日经济新闻）","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.30.0","shortVersion":"4.30.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2502802620"}